As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.
1 Cash-Producing Stock Worth Your Attention and 2 That Underwhelm
1 Healthcare Stock Worth Your Attention and 2 We Avoid
Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.
Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without bevacizumab...
There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading...
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025
SCHD looks well-positioned to outperform significantly if the economy turns south in 2026.
- Number of Lawsuits Increases Fivefold to Over 2,100 Since May - FDA Approves Brain Tumour Warning Global pharmaceutical company...